Biohaven touts surge in Nurtec sales ahead of Pfizer takeover

Nicole DeFeudis

Editor

Forget buyer’s remorse, Pfizer is likely feeling pretty good about its $11.6 billion Biohaven takeover deal following reports of a 57% sales boost for migraine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Biohaven touts surge in Nurtec sales ahead of Pfizer takeover

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Some generics, biosimilar drugmakers say they can withstand tariff impact

UnitedHealth Group CEO Andrew Witty steps down

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bio­haven touts surge in Nurtec sales ahead of Pfiz­er takeover

Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biohaven touts surge in Nurtec sales ahead of Pfizer takeover